Cargando…
Tislelizumab: A Modified Anti-tumor Programmed Death Receptor 1 Antibody
Tislelizumab is an anti-programmed death receptor 1 (PD-1) monoclonal immunoglobulin G 4 antibody developed by BeiGene. The structure of tislelizumab has been modified to maximally inhibit the binding of PD-1 to programmed death ligand 1 (PD-L1) and minimize the binding of tislelizumab to Fcγ recept...
Autores principales: | Zhang, Lin, Geng, Zhihua, Hao, Bo, Geng, Qing |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9358212/ https://www.ncbi.nlm.nih.gov/pubmed/35926155 http://dx.doi.org/10.1177/10732748221111296 |
Ejemplares similares
-
Photoimmunotherapy: A New Paradigm in Solid Tumor
Immunotherapy
por: Peng, Zheng, et al.
Publicado: (2022) -
Prognostic Role of Pathological Complete Response in Early Stage Epithelial Solid Tumors
por: Saltalamacchia, Giuseppe, et al.
Publicado: (2023) -
Phase IA/IB study of single-agent tislelizumab, an investigational anti-PD-1 antibody, in solid tumors
por: Desai, Jayesh, et al.
Publicado: (2020) -
Machine Learning Detects Anti-DENV Signatures in Antibody Repertoire Sequences
por: Horst, Alexander, et al.
Publicado: (2021) -
Digital Slide Assessment for Programmed Death-Ligand 1 Combined Positive Score in Head and Neck Squamous Carcinoma: Focus on Validation and Vision
por: Eccher, Albino, et al.
Publicado: (2021)